Lantus Cost in Missouri 2026: Prices, Coverage, and Savings Options

What Is Insulin Glargine and Why Does Its Price Matter in Missouri?

Insulin glargine is a long-acting basal insulin analog dosed once daily by subcutaneous injection. It is the active ingredient in Lantus (Sanofi), Basaglar (Eli Lilly), Semglee (Viatris), and Rezvoglar (Eli Lilly). The FDA approved the original Lantus formulation based on clinical evidence showing equivalent glycemic control to NPH insulin with a lower nocturnal hypoglycemia rate [1]. The ORIGIN trial (N=12,537, median follow-up 6.2 years) confirmed that insulin glargine titrated to a fasting glucose target of 95 mg/dL did not increase cardiovascular events and produced a neutral effect on cancer outcomes, reinforcing its long-term safety profile [2].

Missouri has roughly 700,000 adults living with diagnosed diabetes, per CDC surveillance data [3]. Access to affordable basal insulin directly affects glycemic outcomes, hospitalization rates, and long-term microvascular complication risk. The American Diabetes Association's 2024 Standards of Care state: "Insulin is necessary for survival in people with type 1 diabetes and may be necessary for people with type 2 diabetes to achieve target glycemic goals" [4]. Pricing barriers that delay or interrupt insulin therapy translate into measurable clinical harm.

Understanding the full cost picture in Missouri requires separating four distinct payment pathways: manufacturer list price, retail pharmacy cash price with discount codes, insurance or Medicaid coverage, and compounded insulin from a 503A pharmacy.

Sanofi List Price vs. Actual Missouri Cash Price

The Sanofi manufacturer list price for Lantus in 2026 is approximately $340 per month for one 10 mL vial (100 units/mL). That number gets widely reported but rarely reflects what patients actually pay at Missouri pharmacies.

GoodRx and similar discount aggregators regularly show cash-pay prices for a 10 mL vial of Lantus ranging from $270 to $310 at major Missouri chains (Walgreens, CVS, Walmart), before any discount code is applied. After applying a free GoodRx coupon, the price at many Missouri locations drops to approximately $35 per month for a standard 10 mL vial, a reduction of roughly 90% from list price. Walmart's private-label ReliOn insulin line (regular and NPH formulations) sits at $25 per vial over the counter, but it does not include a glargine product; patients requiring glargine specifically cannot substitute ReliOn products without physician guidance on dosing conversion [5].

Biosimilar insulin glargine products approved by the FDA as interchangeable with Lantus include Semglee (approved July 2021) [6] and Rezvoglar (approved December 2022) [7]. Because the FDA has granted these products interchangeable status, a pharmacist in Missouri may legally substitute them for Lantus without contacting the prescribing physician, provided the physician has not written "dispense as written." Semglee typically lists below Lantus, and its cash-pay price after discount codes runs $20 to $30 per month at many Missouri pharmacies, making it the lowest-cost branded glargine option short of compounding.

Missouri Medicaid (MO HealthNet) Coverage for Lantus

MO HealthNet covers insulin glargine for type 1 diabetes patients with relatively straightforward criteria. Coverage for type 2 diabetes patients requires prior authorization and documentation that the patient has not achieved glycemic targets on oral agents alone. This distinction matters because approximately 90 to 95% of Missouri's diabetic population has type 2 disease [3], meaning most MO HealthNet enrollees seeking Lantus coverage must complete a prior authorization process.

The prior authorization criteria under MO HealthNet's preferred drug list (PDL) as of 2025 require a prescriber attestation that the patient has an HbA1c above a specified threshold (typically 8.0% or higher) despite optimized oral therapy, and documentation of the prescriber's clinical rationale for choosing insulin glargine over a preferred formulary insulin such as NPH [8]. Formulary placement can shift annually; Missouri providers should verify current PDL status at the MO HealthNet provider portal before prescribing.

Patients enrolled in a Missouri Medicaid managed care organization (MCO), such as Centene's Missouri Care or Anthem's HealthKeepers Plus, may face plan-specific formulary restrictions that differ from the base MO HealthNet PDL. Calling the MCO's pharmacy benefit line before dispensing saves patients from unexpected out-of-pocket charges.

A MO HealthNet enrollee who is denied coverage for Lantus on prior authorization grounds has the right to appeal through the MO HealthNet fair hearing process within 30 days of the denial notice [8]. Telehealth prescribers in Missouri can initiate and submit the prior authorization documentation electronically, which the Missouri Medicaid agency accepts under current e-prescribing rules.

Federal and State Insulin Cap Programs Relevant to Missouri Residents

The Inflation Reduction Act (IRA), signed into law in August 2022, capped Medicare Part D beneficiary out-of-pocket insulin costs at $35 per month per covered insulin product beginning January 1, 2023 [9]. Missouri residents on Medicare who use Lantus or an interchangeable biosimilar pay no more than $35 per fill, regardless of plan design. This cap applies to all Part D plans and Part B (when insulin is administered via an insulin pump covered as durable medical equipment).

The $35 cap does not extend automatically to commercial insurance plans. Some commercial insurers voluntarily adopted a similar cap following industry pressure, but coverage varies by employer plan and carrier. Missouri residents with commercial insurance should check their plan's summary of benefits and coverage document for insulin cost-sharing language.

The federal Low Income Subsidy (LIS/Extra Help) program under Medicare provides additional cost reduction, sometimes bringing insulin copays to $0 for qualifying low-income Medicare beneficiaries in Missouri [10]. Eligibility is income-based; the Social Security Administration manages enrollment.

Sanofi Insulin Savings Programs for Missouri Patients

Sanofi offers two primary patient assistance pathways for Missouri residents who cannot afford Lantus.

The Insulins Valyou Savings Program caps monthly out-of-pocket costs at $99 for uninsured or underinsured patients using any Sanofi insulin, including Lantus, Toujeo, and Admelog [11]. Enrollment is online at Sanofi's patient services portal. Missouri residents with an annual household income below 400% of the federal poverty level may qualify for deeper discounts or free insulin through Sanofi's Patient Assistance Program (PAP), which ships insulin directly to the patient's home or physician's office at no charge [11].

The Sanofi savings card for commercially insured patients reduces the Lantus copay to as low as $0 per month for eligible prescriptions. The card has an annual benefit cap, and patients must have commercial insurance that covers Lantus (government insurance programs such as Medicare or Medicaid make the patient ineligible for the savings card) [11]. A Missouri patient on a high-deductible health plan who has not yet met their deductible can still use the savings card to reduce their cost during the deductible phase.

Lilly's Insulin Value Program similarly caps out-of-pocket costs at $35 per month for Basaglar and Rezvoglar, both insulin glargine products that are FDA-interchangeable with Lantus [12]. Since Rezvoglar is interchangeable, a Missouri pharmacist can legally dispense it in place of Lantus when a savings card for Rezvoglar covers the fill more affordably, provided the prescriber has not written "dispense as written."

Compounded Insulin Glargine in Missouri: Legality and Practicality

Compounded insulin glargine prepared by a state-licensed 503A pharmacy is legal in Missouri. Section 503A of the federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies; they may prepare customized insulin glargine formulations for individual patients based on a valid prescriber order [13]. Missouri compounds under state pharmacy board oversight and must comply with USP Chapter 797 sterile compounding standards.

Compounding a drug that is commercially available (as Lantus is) requires the prescriber to document a clinical reason the commercial product does not meet the patient's needs, such as an allergy to a Lantus excipient (e.g., metacresol or zinc chloride), a required concentration not available commercially, or a specific clinical indication documented in the patient record [13]. Prescribing compounded insulin glargine purely to lower cost, without a documented clinical rationale, sits in a regulatory gray area and may expose the prescriber and pharmacy to FDA scrutiny.

Some Missouri telehealth platforms include access to 503A-compounded insulin glargine as part of a subscription plan, effectively reducing the patient's incremental cost to near zero after the plan fee. Patients using this pathway should confirm the compounding pharmacy holds active Missouri and federal registrations and that the prescriber's documentation of clinical necessity is thorough.

503B outsourcing facilities (larger compounders who produce without individual prescriptions) may NOT compound Lantus under current FDA guidance because insulin glargine is not on the FDA's 503B bulk drug substances list [14]. Missouri patients should verify their compounding pharmacy operates under 503A, not 503B, rules before filling a compounded insulin glargine order.

Insurance Coverage for Lantus in Missouri: Commercial Plans

Commercial insurance formulary placement for Lantus in Missouri varies by plan year, carrier, and employer group. Most large carriers (Blue Cross Blue Shield of Missouri, Cigna, Aetna, UnitedHealthcare) place Lantus on Tier 3 of a standard 5-tier formulary, which typically produces a copay of $50 to $100 per fill after the deductible is met, or 25 to 40% coinsurance before the deductible. Biosimilar alternatives (Semglee, Rezvoglar, Basaglar) are more often placed on Tier 2, at lower cost-sharing [15].

Patients whose commercial plan places Lantus on a non-preferred tier should ask their prescriber about a step therapy exception or a formulary exception. Missouri law (RSMO §376.1550) limits step therapy requirements and gives patients the right to request a step therapy exception when the required first-step drug is contraindicated, has been tried and failed, or will cause a clinically significant adverse event [16]. A telehealth provider can document this exception request electronically using standard prior authorization forms accepted by all major Missouri commercial carriers.

The HealthRX Missouri Lantus Cost Decision Framework below summarizes which savings pathway to pursue based on a patient's insurance status. Patients should work through this framework with their prescriber or pharmacist to identify the lowest legal cost option before their first fill.

Step 1. Confirm the patient's current insurance status: Medicare Part D, Missouri Medicaid (MO HealthNet), commercial insurance, or uninsured.

Step 2. Medicare Part D patients: confirm the $35/month IRA cap applies to their enrolled plan. If using an insulin pump, confirm Part B billing.

Step 3. MO HealthNet patients: check PDL and whether type 1 or type 2 disease. Type 2 patients initiate prior authorization. If denied, file a fair hearing appeal within 30 days.

Step 4. Commercial insurance patients: check formulary tier. If Tier 3 or higher, apply Sanofi savings card. If income-eligible, apply for Sanofi PAP or Insulins Valyou.

Step 5. Uninsured patients: compare GoodRx-discounted Semglee or Rezvoglar cash price against Sanofi's Insulins Valyou $99 cap and Lilly's $35/month Insulin Value Program.

Step 6. Patients with a documented clinical reason for a non-commercial formulation: evaluate 503A compounding through a licensed Missouri pharmacy.

Telehealth Prescribing of Lantus in Missouri

Missouri law permits telehealth prescribing of Schedule II through V controlled substances only under specific conditions, but insulin glargine is not a controlled substance. Lantus may be prescribed via telehealth in Missouri under standard medical practice guidelines without the in-person visit requirements that apply to controlled substances [17].

The Missouri State Board of Registration for the Healing Arts requires that telehealth encounters establish a valid patient-physician relationship, include a sufficient history and physical assessment (which may be conducted via synchronous audio-video), and meet documentation standards equivalent to in-person encounters [17]. A prescriber who has never seen the patient before may initiate insulin glargine therapy via telehealth in Missouri, provided the encounter documentation supports the clinical decision.

Missouri's telehealth parity law (RSMo §376.1900) requires commercial insurers to reimburse covered telehealth services at the same rate as in-person services when the service is covered [18]. This means a Missouri patient receiving a Lantus prescription through a telehealth visit pays the same office visit copay they would pay in person, assuming the service is covered under their plan.

Dosing, Administration, and What to Tell Your Missouri Prescriber

Lantus is administered once daily by subcutaneous injection at the same time each day. The standard starting dose for type 2 diabetes is 10 units per day or 0.1 to 0.2 units per kilogram of body weight per day, titrated upward in 2-unit increments every 3 days until fasting glucose consistently reaches the 80 to 130 mg/dL target range recommended by the ADA's 2024 Standards of Care [4]. Type 1 patients require more individualized dosing that accounts for total daily insulin requirements and the basal-to-bolus ratio.

Injection sites include the abdomen, thigh, and upper arm. Rotating sites within each region reduces lipohypertrophy, a condition that impairs insulin absorption and can cause erratic glycemic control [19]. Missouri patients starting insulin for the first time should receive injection technique training from a certified diabetes care and education specialist (CDCES); the Association of Diabetes Care and Education Specialists maintains a zip-code-searchable directory of Missouri CDCES providers [20].

Lantus must not be mixed with any other insulin in the same syringe. It should be stored in a refrigerator (36 to 46°F) before opening and at room temperature (below 86°F) for up to 28 days after opening. Freezing destroys the formulation [1].

Comparing Lantus to FDA-Interchangeable Biosimilars Available in Missouri

Three FDA-approved interchangeable biosimilars for Lantus are currently available in Missouri pharmacies: Semglee (Viatris, approved July 2021) [6], Rezvoglar (Eli Lilly, approved December 2022) [7], and Basaglar (Eli Lilly, approved December 2015, though not designated interchangeable by the FDA) [21].

Semglee and Rezvoglar hold FDA interchangeable status, meaning the agency has determined they can be substituted for Lantus without any expected difference in safety or effectiveness. Clinical pharmacokinetic and pharmacodynamic studies showed comparable time-action profiles and equivalent insulin receptor binding characteristics to Lantus [6]. Missouri pharmacists can legally substitute these products for Lantus on a prescription written for "insulin glargine" or "Lantus" unless the prescriber specifies "dispense as written."

The practical cost advantage is meaningful. Rezvoglar launched at a list price approximately 78% below Lantus's list price, and Lilly's Insulin Value Program caps the patient's monthly out-of-pocket cost at $35 [12]. For Missouri patients without insurance or with high cost-sharing plans, Rezvoglar through Lilly's savings program is currently the most accessible branded glargine option by price.

Monitoring Requirements and Lab Tests Missouri Providers Should Order

Patients on insulin glargine require periodic HbA1c testing, typically every 3 months when starting therapy or adjusting doses and every 6 months once stable [4]. A baseline comprehensive metabolic panel (CMP) documents renal function before initiating therapy, since renal impairment affects insulin clearance and hypoglycemia risk [19].

Continuous glucose monitoring (CGM) devices, such as the Dexterity Libre 3 or Dexterity Dexcom G7, are covered under many Missouri commercial insurance plans and under Medicare Part B for patients meeting medical necessity criteria [9]. CGM time-in-range data (target: greater than 70% of readings between 70 and 180 mg/dL) increasingly supplements HbA1c as a glycemic outcome measure in clinical practice and is cited in the ADA's 2024 Standards of Care [4].

Hypoglycemia is the primary acute risk of insulin glargine therapy. The ORIGIN trial reported a rate of 1.00 severe hypoglycemic event per 100 patient-years in the glargine arm versus 0.31 in the standard-care arm (P<0.001), underlining the need for structured glucose monitoring, especially during dose titration [2]. Missouri patients should receive a glucagon rescue kit (nasal glucagon or injectable glucagon) at the time of insulin initiation.